Trial Profile
To assess immune-mediated adverse events related to check point's inhibitors in Cancer Immunotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 25 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting